02/09/2021
[email protected]&emid=aEtMclNxRHI2c01QeHVUYTdXSmFzSHJ5YWFlbkFQR3ZZamI5Y3pSaUlQQT0=&ecid=b2xiVDZaNDJid3FzbGlrN0wyUFZCZz09&ecpid=b2xiVDZaNDJid3FzbGlrN0wyUFZCZz09&euid=eGtTNldTS3NWS05lYzY5MHJSNjVxQT09&activity_name=ethealthdailynews_2021-08-29" rel="ugc" target="_blank">https://health.economictimes.indiatimes.com/l.php?url=https%3A%2F%2Fhealth.economictimes.indiatimes.com%2Fnews%2Fpharma%2Fgennova-vax-gets-nod-for-ph-2%2F3-trials%2F85611851&mailer_id=0&item_id=4616867&dt=2021-08-29&utm_source=Mailer&utm_medium=ET_batch&utm_campaign=ethealth_news_2021-08-29&email=[email protected]&emid=aEtMclNxRHI2c01QeHVUYTdXSmFzSHJ5YWFlbkFQR3ZZamI5Y3pSaUlQQT0=&ecid=b2xiVDZaNDJid3FzbGlrN0wyUFZCZz09&ecpid=b2xiVDZaNDJid3FzbGlrN0wyUFZCZz09&euid=eGtTNldTS3NWS05lYzY5MHJSNjVxQT09&activity_name=ethealthdailynews_2021-08-29
India’s first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trails..